Kura Oncology (KURA) Research & Development (2014 - 2026)

Kura Oncology (KURA) has 11 years of Research & Development data on file, last reported at $65.3 million in Q1 2026.

• On a quarterly basis, Research & Development rose 16.6% year-over-year to $65.3 million in Q1 2026; TTM through Mar 2026 was $215.2 million, a 13.46% increase from a year earlier, with the FY2025 full-year figure at $251.1 million, up 47.72% from the prior year.
• Research & Development for Q1 2026 stood at $65.3 million, up from $56.0 million in the prior quarter.
• Over the last five years, Research & Development for KURA reached as high as $65.3 million in Q1 2026 and fell as low as $20.9 million in Q1 2022.
• Historically, Research & Development has averaged $35.7 million across 5 years, with a median of $30.9 million in 2023.
• Across the five-year window, Research & Development gained 2.9% in 2022 and surged 60.66% in 2024, its largest moves.
• Year by year, Research & Development stood at $22.7 million in 2022, then jumped by 43.52% to $32.5 million in 2023, then jumped by 60.66% to $52.3 million in 2024, then increased by 7.09% to $56.0 million in 2025, then grew by 16.6% to $65.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $65.3 million in Q1 2026, $56.0 million in Q1 2025, and $52.3 million in Q4 2024.